Light, sound and microcurrent entrainment. From a 10-session starter to our 51-protocol flagship.
Compare all devices →From the first alpha-rhythm studies to today's gamma research.
From in-home neurofeedback practices to university research labs.
Register →From two-week sleep changes to decade-long daily practices.
For more than three decades, MindAlive's DAVID devices have been studied worldwide. Independent research confirms that Audio-Visual Entrainment (AVE) is safe, drug-free, and effective in supporting learning, cognition, mental health, pain relief, and sleep. DAVID's clinical evidence base spans 35+ years of independent research across psychiatry, neurology, sleep medicine, and rehabilitation. Use this overview for patient education, protocol decisions, and reimbursement conversations.
DAVID devices combine three independent, drug-free technologies. Each has its own evidence base — together they give you a single tool to support cognition, mood, pain, and sleep.
Rhythmic light pulses through glasses combined with synchronized tones guide your brain toward specific frequency states — alert beta, calm alpha, deep theta, or restorative delta.
A gentle micro-current delivered through ear-clip electrodes. Studied since the 1970s for anxiety, depression, and insomnia — FDA-cleared as a medical device category in the US.
Targeted micro-current applied to specific points (forehead, mastoids, or body) to support muscle relaxation, tension headaches, and chronic pain conditions like fibromyalgia.
Each DAVID program targets a specific brain-wave state and condition. Here are the five most-studied areas — with the studies, what was measured, and which program supports them. Use this overview during intake to match patient goals to specific protocols. Each category links a published finding to a frequency range and the AVE/CES/MET modality that produced it.
DAVID devices include pre-set programs for learning, concentration, and memory enhancement. Beta-band protocols (15–22 Hz) for attention training, ready-to-use in session.
Find your deviceView protocols →DAVID's theta and alpha protocols are designed for memory recall and cognitive longevity. Use 6 Hz theta protocols 3×/week for cognitive maintenance in older patients.
Find your deviceView protocols →From seasonal depression to everyday stress, AVE offers a safe, drug-free approach to mental well-being. Adjunct to CBT and exposure therapy. CES protocols billable in many jurisdictions.
Find your deviceView protocols →Designed for chronic pain, tension headaches, and fibromyalgia — used daily or as needed. MET + theta-AVE combination shows synergistic effect for fibromyalgia patients.
Find your deviceView protocols →Pre-programmed sleep and relaxation sessions guide you into deep, restorative rest. Recommend 20-min delta protocol at bedtime for insomnia and shift-work disruption.
Find your deviceView protocols →Filter by modality or search by keyword. Each entry links a published study to its condition, finding, and the DAVID modality (AVE, CES, or MET) used.
| Condition | Study | Key finding | Modality |
|---|---|---|---|
| Physiology | Thomas & Siever, 1989 | Early documentation that AVE produces measurable changes in muscle tension and peripheral blood-flow. | AVE |
| Chronic pain | Gagnon & Boersma, 1992 | AVE applied to chronic pain patients reduced subjective pain ratings and supported deeper relaxation. | AVE |
| Dissociation | Leonard, Telch & Harrington, 1999 | Established the experimental paradigm for measuring AVE-related dissociation and state shifts. | AVE |
| Fibromyalgia | Berg, Mueller, Seibel & Siever, 1999 | AVE combined with nutritional support improved fibromyalgia pain and cognitive clarity. | AVE |
| Chronic fatigue | Trudeau, 1999 | 18 Hz beta AVE improved attention and concentration measures in CFS patients. | AVE |
| ADHD / Behavior | Joyce & Siever, 2000 | Daily AVE in school setting reduced behavior incidents and improved engagement. | AVE |
| Anxiety | Leonard, Telch & Harrington, 2000 | Documented fear-response profile to induced dissociation states — informs AVE safety profile. | AVE |
| Education | Joyce, 2001 | Report to Minnesota Dept. of Education on AVE in special-ed classrooms — improved attention and behavior. | AVE |
| Learning | Atsu, 2003 | College students using AVE showed accelerated learning and improved retention vs. traditional study. | AVE |
| Stress biology | Fabian et al., 2004 | AVE-style photo-acoustic stimulation increased stress-protective Hsp70 protein in saliva. | AVE |
| Depression (seniors) | Berg & Siever, 2004 | AVE in depressed community-dwelling seniors at fall-risk produced mood and balance improvements. | AVE |
| Anxiety / exposure | Powers, Smits & Telch, 2004 | Placebo-controlled trial on safety-behaviour utilisation in exposure therapy — informs anxiety protocols. | AVE |
| Social anxiety | Smits et al., 2006 | Videotape feedback enhances exposure-based treatment for social anxiety — supporting research. | AVE |
| Pain perception | Horowitz & Telch, 2007 | Experimental investigation: induced dissociation states altered pain perception and tolerance. | AVE |
| Cognitive decline | Budzynski, Budzynski & Tang, 2007 | Brain-brightening protocols documented for cognitive decline and ageing populations. | AVE |
| Phobias | Wolitzky-Taylor et al., 2008 | Meta-analysis of psychological treatments for specific phobias — informs AVE-adjunct anxiety protocols. | AVE |
| Seasonal mood (SAD) | Berg & Siever, 2009 | Morning AVE produced improvement in SAD comparable to standard bright-light therapy. | AVE |
| Memory | Wuchrer, 2009 | University study examining AVE's effects on memory recall and concentration tasks. | AVE |
| Addiction recovery | Pigott & Dawe, 2009 | AVE/neurotherapy combined with mindfulness supported wellness in early addiction recovery. | AVECES |
| Academic worry | Wolitzky-Taylor & Telch, 2010 | Randomized controlled trial of self-administered interventions for pathological worry in students. | AVE |
| Autism | Naeeimi et al., 2013 | Audio-visual stimulation improved executive-function tasks in children with high-functioning autism. | AVE |
| Memory (seniors) | Palmquist, 2014 | AVE brain-brightening protocols improved memory in middle-aged and older adults. | AVE |
| Auditory processing | Impey & Knott, 2015 | Pilot study of tDCS effects on auditory discrimination — informs CES-adjacent applications. | CES |
| Mechanism | Impey et al., 2017 | Mechanistic investigation of NMDA receptor involvement in transcranial stimulation responses. | CES |
| Episodic memory | Roberts, Clarke, Addante & Ranganath, 2018 | Entrainment increased theta oscillations and improved episodic-memory tasks. | AVE |
| Alzheimer's (prodromal) | He et al., 2021 | Feasibility trial: gamma-frequency sensory stimulation tolerated and beneficial in prodromal Alzheimer's. | AVE |
| Dyslexia | Soualhi & Dekkiche, 2025 | Combined AVE + multi-sensory (VAKT) intervention improved dyslexia symptoms in school-age students. | AVE |
| Pseudobulbar affect | Al-Salihy, 2025 | Two case studies showed AVE therapy reduced symptoms of pseudobulbar affect. | AVE |
Across more than three decades, independent studies confirm that DAVID devices are safe and effective. They have shown benefits in learning, cognition, anxiety, depression, pain, and sleep — consistently, and without harmful side effects. DAVID's evidence base spans 35+ years of independent research across psychiatry, neurology, pain medicine, and sleep. Meaningful effect sizes for the target indication, drug-free administration, and zero serious adverse events reported.
DAVID devices are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider for medical advice.
